Capstone Investments Upgrades Talecris Biotherapeutics (TLCR) to Buy; Clsoing In On Completion Of Acquisition
Tweet Send to a Friend
Capstone Investments upgraded Talecris Biotherapeutics (NASDAQ: TLCR) from Hold to Buy. PT upped $1 to $27.
Capstone analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Capstone analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
